Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis

1 Followers

RARE Stock Chart & Stats

MX$256.00MX$0.00(0.00%)
At close:
Mex$300Mex$400Aug 17Sep 3Sep 29
Day’s Range
MXN 256.00 - MXN 256.00
52-Week Range
MXN 240.00 - MXN 811.00
Previous Close
MXN 256.00
Volume
0
Average Volume (3M)
1
Market Cap
MXN 29.14B
Enterprise Value
MXN 2.45B
Total Cash (Recent Filing)
MXN 266.00M
Total Debt (Recent Filing)
MXN 1.19B
Price to Earnings (P/E)
―
Beta
0.14
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
40.81
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margin

Strong revenue momentum combined with very high gross margins indicates improving commercial traction and attractive product economics. If sustained, this profile can provide increasing resources to fund launches, support selective pipeline investment, and strengthen the company’s ability to approach profitability.

Expanded Rare-Disease Franchise

Reaching six approved medicines broadens Ultragenyx’s commercial platform and adds two gene therapies to its rare-disease franchise. Multiple products and specialized treatment expertise can support durable growth, improve market reach, and reduce reliance on a single development outcome.

Nondilutive Funding And Profitability Plan

The expected $350 million of nondilutive PRV proceeds improves funding flexibility without an equity raise, while management’s 2027 plan targets lower R&D, positive operating cash flow, and GAAP profitability. Execution would materially improve self-funding capacity and financial resilience.

Bears Say

Persistent Losses And Cash Burn

Large negative operating and free cash flow show that the business has not yet converted commercial growth into internal funding. Continued cash consumption can constrain investment choices and increase dependence on successful launches, cost reductions, or additional capital before profitability is achieved.

Negative Equity And Balance-Sheet Risk

Negative equity reflects accumulated losses that have more than offset invested capital, weakening financial flexibility. The differing debt figures across periods add uncertainty to the capital structure, while the combination increases sensitivity to execution setbacks until sustained profits rebuild the balance sheet.

Pipeline Setbacks And Portfolio Reduction

The GTX-102 failure and UX701 termination reduce late-stage pipeline breadth and remove potential future growth drivers. Workforce and portfolio reductions may improve efficiency, but they also signal narrower development capacity and leave future expansion more dependent on existing products and new launches.

Ultragenyx Pharmaceutical News

RARE FAQ

What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was Mex$240.00 and its highest was Mex$811.00 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is Mex$29.14B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s next earnings report is estimated for Feb 18, 2027 (not yet confirmed), which is in 100 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Nov 03, 2026. The company reported -Mex$21.606 earnings per share for the quarter, missing the consensus estimate of -Mex$20.488 by -Mex$1.118.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is 40.81.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 101,924,065 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -Mex$21.606 in its last earnings report, missing expectations of -Mex$20.488. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Hedge funds hold Ultragenyx Pharmaceutical shares: hedge funds decreased their holdings by 85.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology